New York-based Formation Bio, an AI-native pharma company focused on accelerating drug development, revealed that its ...

The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi ...

Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

Formation Bio’s subsidiary, Libertas Bio, has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi.

The company’s product pipeline include ASN008, Gusacitinib and Sprifermin. Its pipeline treats atopic dermatitis, chronic hand eczema and knee osteoarthritis. Formation Bio carries out platform such ...

Zura Bio has initiated the double-blind Phase II TibuSURE trial to assess the humanised tetravalent bispecific dual-antagonist antibody, tibulizumab, in treating systemic sclerosis (SSc), also ...

Gusacitinib is another JAK/SYK kinase inhibitor in the phase 1b RCT. It is used at the oral dose of 20 mg, 40 mg and 80 mg versus placebo for 4 weeks in 36 patients with moderate to severe AD. Results ...

Both gusacitinib and ASN008 were bought from Asana BioSciences in 2022, while sprifermin was licensed from Merck KGaA. “By partnering with Formation Bio, ...

Gusacitinib is an oral dual JAK and spleen tyrosine kinase (SYK) inhibitor under development to treat chronic hand eczema. The investigational drug, licensed to Libertas Bio from Asana BioSciences ...

Eczema is an inflammatory condition that can cause itchy, scaly, discolored skin on the fingers and hands. Learn about natural remedies, prevention strategies, and more.